At her Senate confirmation hearing for FDA commissioner, Heidi Overton said she would follow the law regarding vaccine and mifepristone decisions and affirmed both as safe and effective based on existing evidence. She reiterated support for recommended childhood vaccines, including MMR, amid questioning that referenced the administration’s earlier claims about measles vaccine risk. Lawmakers probed whether Overton would align agency guidance with political direction, while also pressing on how the FDA should manage speed for new therapies and its stance toward research and drug development reforms. The hearing reflected concerns about prior FDA turbulence and perceived inconsistency in decision-making frameworks. In parallel, the nomination debate highlighted vaccine policy as a lightning-rod issue, with senators asking for clarity on scientific standards versus executive preferences. The outcome is not yet a regulatory decision, but the exchange signals where the agency’s leadership may set priorities—clinical trial acceleration, regulatory predictability, and stability in evidence-based determinations.